Trials / Unknown
UnknownNCT00501332
Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Maxygen Holdings Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigation of the safety and efficacy of Maxy-G34 in breast cancer patients treated with TAC chemotherapy. Maxy-G34 will be given as a single injection during each cycle of chemotherapy, for a planned total of six chemotherapy cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Maxy-G34 | Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles. |
Timeline
- Start date
- 2007-07-01
- First posted
- 2007-07-16
- Last updated
- 2007-12-24
Locations
15 sites across 4 countries: Poland, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00501332. Inclusion in this directory is not an endorsement.